ASCEnD is an open label, 1:1 randomised, controlled, pragmatic trial which compares the clinical and cost-effectiveness of an aripriprazole/sertraline combination with quetiapine in the treatment of bipolar depression.
The study is being led by Dr Stuart Watson of Newcastle University and Cumbria, Northumberland, Tyne & Wear NHS Foundation Trust. You can find out more about the rest of the team here: Our Team
You can find which sites around the UK are recruiting to the study here: Sites
Funding
The trial is funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment (HTA) Programme - Project reference number NIHR132773).
Sponsorship
The Study is sponsored by Cumbria, Northumberland, Tyne & Wear NHS Foundation Trust.
Management
The trial is managed by Newcastle Clinical Trials Unit (NCTU) - UKCRC Registered Clinical Trials Unit.
